# Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma

> **NCT06788600** · — · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Epstein-Barr Virus Associated Lymphoma

## Interventions

- **DRUG:** EBV mRNA vaccine (WGc-043)

## Key facts

- **NCT ID:** NCT06788600
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06788600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06788600, "Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06788600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*